These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15473963)

  • 1. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.
    Hutter-Paier B; Huttunen HJ; Puglielli L; Eckman CB; Kim DY; Hofmeister A; Moir RD; Domnitz SB; Frosch MP; Windisch M; Kovacs DM
    Neuron; 2004 Oct; 44(2):227-38. PubMed ID: 15473963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.
    Puglielli L; Konopka G; Pack-Chung E; Ingano LA; Berezovska O; Hyman BT; Chang TY; Tanzi RE; Kovacs DM
    Nat Cell Biol; 2001 Oct; 3(10):905-12. PubMed ID: 11584272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease.
    Timmer NM; Herbert MK; Kleinovink JW; Kiliaan AJ; De Waal RM; Verbeek MM
    Neuropathol Appl Neurobiol; 2010 Oct; 36(6):478-86. PubMed ID: 20831743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein.
    Puglielli L; Ellis BC; Ingano LA; Kovacs DM
    J Mol Neurosci; 2004; 24(1):93-6. PubMed ID: 15314256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
    Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
    Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.
    Leon WC; Canneva F; Partridge V; Allard S; Ferretti MT; DeWilde A; Vercauteren F; Atifeh R; Ducatenzeiler A; Klein W; Szyf M; Alhonen L; Cuello AC
    J Alzheimers Dis; 2010; 20(1):113-26. PubMed ID: 20164597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
    Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
    J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Refolo LM; Pappolla MA; LaFrancois J; Malester B; Schmidt SD; Thomas-Bryant T; Tint GS; Wang R; Mercken M; Petanceska SS; Duff KE
    Neurobiol Dis; 2001 Oct; 8(5):890-9. PubMed ID: 11592856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of ACAT-1 reduces amyloidogenic processing of APP.
    Huttunen HJ; Greco C; Kovacs DM
    FEBS Lett; 2007 Apr; 581(8):1688-92. PubMed ID: 17412327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.
    Amtul Z; Wang L; Westaway D; Rozmahel RF
    Neuroscience; 2010 Aug; 169(2):781-6. PubMed ID: 20493928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.
    Lord A; Gumucio A; Englund H; Sehlin D; Sundquist VS; Söderberg L; Möller C; Gellerfors P; Lannfelt L; Pettersson FE; Nilsson LN
    Neurobiol Dis; 2009 Dec; 36(3):425-34. PubMed ID: 19703562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.
    Weiner HL; Lemere CA; Maron R; Spooner ET; Grenfell TJ; Mori C; Issazadeh S; Hancock WW; Selkoe DJ
    Ann Neurol; 2000 Oct; 48(4):567-79. PubMed ID: 11026440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease.
    Onozuka H; Nakajima A; Matsuzaki K; Shin RW; Ogino K; Saigusa D; Tetsu N; Yokosuka A; Sashida Y; Mimaki Y; Yamakuni T; Ohizumi Y
    J Pharmacol Exp Ther; 2008 Sep; 326(3):739-44. PubMed ID: 18544674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
    Feng Z; Chang Y; Cheng Y; Zhang BL; Qu ZW; Qin C; Zhang JT
    J Pineal Res; 2004 Sep; 37(2):129-36. PubMed ID: 15298672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
    Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC
    J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome.
    Abrahamson EE; Ikonomovic MD; Ciallella JR; Hope CE; Paljug WR; Isanski BA; Flood DG; Clark RS; DeKosky ST
    Exp Neurol; 2006 Feb; 197(2):437-50. PubMed ID: 16300758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.